Dr David Borenstein, LDN Radio Show (LDN, low dose naltrexone)

Dr David Borenstein, LDN Radio Show (LDN, low dose naltrexone) from LDN Research Trust on Vimeo. Dr David Borenstein shares his Low Dose Naltrexone (LDN) experience on the LDN Radio Show with Linda Elsegood. Dr David Borenstein obtained his medical degree from the Technion Faculty of Medicine in Haifa, Israel and completed his internship at […]

Dr David Borenstein, LDN Radio Show 28 Dec 2016 (LDN, low dose naltrexone)

Dr David Borenstein, LDN Radio Show 28 Dec 2016 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo. Linda Elsegood: Today we are joined by Dr. David Bornstein.  Thank you for joining us, David.  Dr David Borenstein: Thank you for having me.  Linda Elsegood: For those people who haven’t heard of you yet, could […]

Low-Dose Naltrexone for Pruritus in Systemic Sclerosis (Abstract)

Low-Dose Naltrexone for Pruritus in Systemic Sclerosis Int J Rheumatol 12 September 2011 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171757/ Pruritus is a common symptom in systemic sclerosis (SSc), an autoimmune disease which causes fibrosis and vasculopathy in skin, lung, and gastrointestinal tract (GIT). Unfortunately, pruritus has limited treatment options in this disease. Pilot trials of low-dose naltrexone hydrochloride (LDN) for […]

Low-Dose Naltrexone (LDN) Treatment for Crohn’s Disease (CD)… (Abstract)

Low-Dose Naltrexone (LDN) Treatment for Crohn’s Disease (CD): A Tertiary Care Center Experience Am J Gastroenterol October 2011 https://journals.lww.com/ajg/Fulltext/2011/10002/Low_Dose_Naltrexone__LDN__Treatment_for_Crohn_s.1223.aspx Purpose: In recent years, there have been many advances in the treatment of CD therapy; including the development of anti-tumor necrosis factor alpha antibodies. However, despite these advances, about 20% of patients do not respond to […]

Safety and tolerability of Low-Dose Naltrexone therapy in children with moderate to severe Crohn’s disease… (Abstract)

Safety and tolerability of Low-Dose Naltrexone therapy in children with moderate to severe Crohn’s disease: a pilot study J Clin Gastroenterol 01 April 2014 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586944/ Background There is an unmet need for safe and effective medicines to treat children with Crohn’s disease. Recently, investigations have shown an association between endogenous opioid peptides and inflammatory cells. […]

Immunological changes in IBD patients responding to low-dose naltrexone treatment (Abstract)

P388 Immunological changes in IBD patients responding to low-dose naltrexone treatment J Crohn’s and Colitis 01 February 2012 https://academic.oup.com/ecco-jcc/article/6/Supplement_1/S164/369091 LDN treatment was successful in part of the IBD patients not responding to other medication. Whether the CD16+ CD62-L+ CD14 monocyte population is a direct target of the opioid growth factor opioid growth factor receptor signaling […]

Low-Dose Naltrexone Therapy Improves Active Ulcerative Colitis (Abstract)

P-015 YI Low-Dose Naltrexone Therapy Improves Active Ulcerative Colitis Inflam Bowel Dis 01 December 2013 https://academic.oup.com/ibdjournal/search-results?page=1&q=Low-Dose%20Naltrexone%20Therapy%20Improves%20Active%20Ulcerative%20Colitis&fl_SiteID=6136&SearchSourceType=1&allJournals=1 Low-dose naltrexone (LDN) has shown promise in several clinical studies as a safe and effective treatment for Crohn’s disease (CD). Naltrexone is an opioid receptor antagonist. It acts as a competitive antagonist at several opioid receptor sites, showing the highest […]

Low dose naltrexone in therapy resistant IBD, a case series (Abstract)

P418 Low dose naltrexone in therapy resistant IBD, a case series J Crohn’s and Colitis February 2014 https://www.gastrojournal.org/article/S0016-5085(14)61660-7/pdf Introduction: Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic relapsing bowel disorders. Several established drug therapies exist, but some patients become resistant to these. For these patients, new treatments are urgently […]

Low Dose Naltrexone in the Treatment of Crohn’s Disease: A Case Series (Abstract)

Tu1365 Low Dose Naltrexone in the Treatment of Crohn’s Disease: A Case Series Gastroenterology April 2015 https://www.gastrojournal.org/article/S0016-5085(15)32952-8/abstract INTRODUCTION:: Crohn’s disease, a form of inflammatory bowel disease (IBD), is a chronic, relapsing condition that may evade remission despite new therapies. Many patients after years of disease may become resistant to previously effective treatments and thus different […]

Therapy with the Opioid Antagonist Naltrexone Promotes Mucosal Healing in Active Crohn’s Disease… (Abstract)

Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial Dig Dis Sci July 2011 https://pubmed.ncbi.nlm.nih.gov/21380937/  Background: Endogenous opioid peptides have been shown to play a role in the development and/or perpetuation of inflammation. We hypothesize that the endogenous opioid system is involved in inflammatory bowel disease, and […]